Comparison of inhibitory effect of rifalazil and rifampicin against Mycobacterium ulcerans infection induced in mice

Kekkaku

Volumn 79, Issue 5, 2004, Pages 333-339

  Nakanaga, Kazue ^a,c   Saito, Hajime ^a   Ishii, Norihisa ^a   Goto, Masamichi ^b  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

Author keywords

Inhibitory effect; Murine infection model; Mycobacterium ulcerans; Rifalazil; Rifampicin

Indexed keywords

AMIKACIN; DAPSONE; RIFALAZIL; RIFAMPICIN; STREPTOMYCIN;

ANIMAL MODEL; ARTICLE; BACTERIUM CULTURE; BURULI ULCER; CLINICAL FEATURE; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; ERYTHEMA; FOOT PAD; IN VIVO STUDY; INHIBITION KINETICS; MOUSE; MYCOBACTERIUM ULCERANS; NONHUMAN; SKIN NECROSIS; SKIN ULCER; TREATMENT OUTCOME;

ANIMALS; ANTIBIOTICS, ANTITUBERCULAR; FEMALE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM INFECTIONS, ATYPICAL; MYCOBACTERIUM ULCERANS; RIFAMPIN; RIFAMYCINS; TUBERCULOSIS, CUTANEOUS;

EID: 3042697422     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Horsburgh CR Jr., Meyers WM: Buruli ulcer. In: Pathology of Emerging Infections, Horsburgh CR Jr., Nelson AM, eds., American Society for Microbiology Press, Washington, DC, 1997, 119-126.
2. van der Werf TS, van der Graaf WTA, Tappero JW, et al.: Mycobacterium ulcerans infection. Lancet. 1999; 354: 1013-1018.
3. WHO: Buruli ulcer disease. Mycobacterium ulcerans infection. Wkly Epidemiol Rec. 2002: 77: 271-275.
4. WHO: Buruli ulcer. Mycobacterium ulcerans infection. Wkly Epidemiol Rec. 2002; 77: 165-166.
5. WHO: Buruli ulcer. Global Situation. Website: http://www. who.int/gtb_buruli/global-situation/index.html
6. WHO: Buruli ulcer. Global Buruli Ulcer Initiative. Website: http://www.who.int/gtb_buruli/initiative/index.html
7. George KM, Chatterjee D, Gunawardana G, et al.: Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science. 1999; 283:854-857.
8. Portaels F, Traore H, De Ridder K, et al.: In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother. 1998; 42: 2070-2073.
9. Thangaraj HS, Adjei O, Allen BW, et al.: In vitro activity of ciprofloxacin, sparfloxacin, ofloxacin, amikacin and rifampicin against Ghanaian isolates of Mycobacterium ulcerans J Antimicrob Chemother. 2000; 45: 231-233.
10. Dhople AM: In vitro activity of KRM-1648, either singly or in combination with ofloxacin, against Mycobacterium ulcerans. Int J Antimicrob Agents. 2001; 17: 57-61.
11. Dhople AM: Antimicrobial activities of dihydrofolate reductase inhibitors, used singly or in combination with dapsone, against Mycobacterium ulcerans. J Antimicrob Chemother. 2001; 47: 93-96.
12. Dhople AM, Namba K: in vitro activity of sitafloxacin (DU-6859a) alone, or in combination with rifampicin, against Mycobacterium ulcerans. J Antimicrob Chemother. 2002; 50: 727-729.
13. Dega H, Robert J, Bonnafous P, et al.: Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother. 2000; 44: 2367-2372.
14. Dhople AM: In vivo susceptibility of Mycobacterium ulcerans to KRM-1648, a new benzoxazinorifamycin, in comparison with rifampicin. Anti-mycobacterial activity of KRM-1648. Arzneimittelforschung. 2001; 51: 501-505.
15. Bentoucha A, Robert J, Dega H, et al.: Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother. 2001; 45: 3109-3112.
16. Dega H, Bentoucha A, Robert J, et al.: Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother. 2002; 46: 3193-3196.
17. Espey DK, Djomand G, Diomande I, et al.: A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis. 2002; 6: 60-65.
18. WHO: Bumli ulcer disease. Mycobacterium ulcerans infection. Wkly Epidemiol Rec. 2003; 78: 163-168.
19. McClatchy JK, Waggoner RF, Kanes W, et al.: Isolation of Mycobacteria from clinical specimens by use of selective 7H11 medium. Am J Clin Pathol. 1976;65: 412-415.
20. Yamane T, Hashizume T, Yamashita K, et al.: Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chem Pharm Bull (Tokyo). 1993; 41: 148-155.
21. Saito H, Tomioka H, Sato K, et al.: In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother. 1991; 35:542-547.
22. Tomioka H, Saito H, Sato K, et al.: Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother. 1992; 36: 387-393.
23. Yamamoto Y, Saito H, Tomioka H, et al.: In vitro and in vivo activities of KRM-1648, a newly synthesized benzoxazinorifamycin, against Mycobacterium marinum. Zbl Bakt. 1992; 277: 204-209.
24. Saito H, Tomioka H, Sato K, et al.: In vitro and in vivo anti-leprosy activities of benzoxazinorifamycin (KRM-1648) and clarithromycin, Proceedings of Twenty-Seventh U.S.-Japan Cooperative Medical Science Program. 1992; 38-42.
25. Emori M, Saito H, Sato K, et al.: Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits. Antimicrob Agents Chemother. 1993; 37: 722-728.
26. Saito H, Tomioka H, Sato K, et al.: Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice. Tuberc Lung Dis. 1995; 76: 51-58.
27. Hirata T, Saito H, Tomioka H, et al.: In vitro and in vivo activities of the benzoxazinorifamycin KRM-1648 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1995; 39: 2295-2303.
28. Yamamoto T, Amitani R, Suzuki K, et al.: Activity of KRM-1648 alone or in combination with both ethambutol and kanamycin or clarithromycin against Mycobacterium intracellulare infections in beige mice. Antimicrob Agents Chemother. 1996; 40: 429-432.
29. Bermudez LE, Kolonboski P, Young LS, et al.: Activity of KRM-1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium ovium complex in beige mouse model of disseminated infection. Antimicrob Agents Chemother. 1994; 38: 1844-1848.
30. Klemens SP, Grossi MA, Cynamon MH: Activity of KRM-1648, a new benzoxazinorifamycin, against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother. 1994; 38: 2245-2248.
31. Klemens SP, Cynamon MH: Activity of KRM-1648 in combination with isoniazid against Mycobacterium tuberculosis in a mufine model. Antimicrob Agents Chemother. 1996; 40: 298-301.
32. Baohong JI, Lounis N, Truffot-Pernot C, et al.: How effective is KRM-1648 in treatment of disseminated Mycobacterium avium complex infections in beige mice. Antimicrob Agents Chemother. 1996; 40: 437-442.
33. George KM, Pascopella L, Welty DM, et al.: A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun. 2000; 68: 877-883.
34. Pahlevan AA, Wright DJ, Andrews C, et al.: The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol. 1999; 163: 3928-3935.
35. Gomez A, Mve-Obiang A, Vray B, et al.: Biochemical and genetic evidence for phospholipase C activity in Mycobacterium ulcerans. Infect Immun. 2000; 68: 2995-2997.
36. Mve-Obiang A, Lee RE, Portaels F, et al.: Heterogeneity of mycolactones produced by clinical isolates of Mycobacterium ulcerans: implications for virulence. Infect Immun. 2003; 71: 774-783.